List view / Grid view
14 April 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced the submission of a new drug application to the U.S. Food and Drug Administration for a fixed-dose combination of atazanavir sulfate...
14 April 2014 | By Biogen Idec
Biogen Idec will present more than 60 company-sponsored platform and poster presentations on data supporting its marketed and investigational therapies for neurological diseases at the 66th American Academy of Neurology Annual Meeting...
11 April 2014 | By The European Medicines Agency
The Pharmacovigilance Risk Assessment Committee gave a recommendation on one safety review and started four new safety reviews at its April meeting...
11 April 2014 | By Merck
Merck announced interim results from the ongoing C-WORTHy study, a multi-arm Phase 2 clinical trial evaluating the efficacy and safety of an all-oral, once-daily regimen combining MK-5172...
11 April 2014 | By Daiichi Sankyo
As announced in a release dated April 7, 2014, pursuant to a merger transaction, whereby Daiichi Sankyo Company, Limited has agreed with Sun Pharmaceutical Industries Ltd...
10 April 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced Phase III results from the global HALLMARK-Dual study investigating the all-oral, interferon- and ribavirin-free regimen of daclatasvir...
10 April 2014 | By Biogen Idec
Biogen Idec announced the appointment of Adam M. Koppel, M.D., Ph.D., as senior vice president and chief strategy officer, effective May 15, 2014...
10 April 2014 | By Abbott
Abbott announced it has completed enrollment of three clinical trials to support approvals of the company's revolutionary Absorb™ Bioresorbable Vascular Scaffold...
9 April 2014 | By The European Medicines Agency
Targeted discussions with key stakeholders in May...
9 April 2014 | By Teva
Teva Pharmaceutical Industries Ltd. announces the approval of the generic equivalent to Lovaza®...
9 April 2014 | By Johnson & Johnson
Janssen Research & Development, LLC (“Janssen”) today announced the submission of a supplemental New Drug Application (sNDA) for IMBRUVICA™ (ibrutinib) to the U.S. Food and Drug Administration (FDA) by its collaboration partner Pharmacyclics, Inc. This regulatory submission is based on data from the Phase 3 RESONATE™ study in relapsed or…
9 April 2014 | By Novartis
Novartis announced the appointment of Jeff George as Division Head of Alcon, effective May 1, 2014...
8 April 2014 | By OncoEthix
OncoEthix announced that the interim results from its ongoing Phase I clinical trial of OTX015, in patients with hematologic malignancies, were presented at the annual American Association of Cancer Research...
8 April 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced that the U.S. Food and Drug Administration has approved Pradaxa® (dabigatran etexilate) for the treatment of DVT and PE...
7 April 2014 | By The European Medicines Agency
In a meeting at the European Medicines Agency on 4 April 2014, the EMA’s Executive Director, Prof. Guido Rasi, and the National Manager of the Australian Therapeutic Goods AdministrationExternal link icon, Prof. John Skerritt, announced that the two regulators have agreed to share the full assessment reports...
